WO2026011008 - EXPRESSION CONTROL BY SKELETAL MUSCLE-EXPRESSED MIRNAS
National phase entry is expected:
Publication Number
WO/2026/011008
Publication Date
08.01.2026
International Application No.
PCT/US2025/036161
International Filing Date
01.07.2025
Title **
[English]
EXPRESSION CONTROL BY SKELETAL MUSCLE-EXPRESSED MIRNAS
[French]
CONTRÔLE D'EXPRESSION PAR MIARN EXPRIMÉS PAR LES MUSCLES SQUELETTIQUES
Applicants **
KATE THERAPEUTICS, INC.
Inventors
SESHADRI, Saurav
TABEBORDBAR, Sharif
TABEBORDBAR, Shayan
Priority Data
63/666,892
02.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2224 | |
| EPO | Filing, Examination, Granting | 10895 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2380 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,546
Contact Us
Abstract[English]
The present invention provides recombinant nucleic acids that express a transgene and at least one binding site of miR-206 and/or at least one binding site of miR-128-3p such that expression of the transgene is inhibited by the presence of endogenous miR-206 and/or miR-128-3p in skeletal muscle.[French]
La présente invention concerne des acides nucléiques recombinants qui expriment un transgène et au moins un site de liaison de miR-206 et/ou au moins un site de liaison de miR-128-3 p de sorte que l'expression du transgène est inhibée par la présence de miR-206 endogène et/ou de miR-128-3 p dans les muscles squelettiques.